Navigation Links
Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
Date:12/27/2007

ittee for Orphan Medicinal Products of the European Medicines Agency, or EMEA, granted orphan medicinal product designation to PDX for the treatment of patients with PTCL

About the Data Monitoring Committee (DMC)

The DMC is comprised of independent medical experts and was established by Allos as part of the Company's compliance with good clinical practice guidelines. The DMC is responsible for monitoring the on-going safety of patients participating in the PROPEL trial and for conducting formal interim safety assessments of trial results.

About Peripheral T-cell Lymphoma

Peripheral T-cell lymphomas, or PTCLs, are a biologically diverse and uncommon group of blood cancers that account for approximately 10% to 15% of all cases of non-Hodgkin's lymphoma, or about 7,100 patients annually. The average five-year survival rate for PTCL patients is approximately 25%. There are currently no pharmaceutical agents approved for use in the treatment of either first-line or relapsed or refractory PTCL.

About PDX (pralatrexate)

PDX is a novel, small molecule chemotherapeutic agent that inhibits dihydrofolate reductase, or DHFR, a folic acid (folate)-dependent enzyme involved in the building of nucleic acid, or DNA, and other processes. PDX was rationally designed for efficient transport into tumor cells via the reduced folate carrier, or RFC-1, and effective intracellular drug retention. The Company believes these biochemical features, together with preclinical and clinical data in a variety of tumors, suggest that PDX may have a favorable safety and efficacy profile relative to methotrexate and certain other DHFR inhibitors.

About Allos Therapeutics, Inc.

Allos Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a piv
'/>"/>

SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)...  UBM Canon brings MEDevice San Diego Conference & ... on September 1-2, 2015, with a multi-track conference program ... Business Development track will be a panel on How ... featuring Renee Ryan , Vice President of Venture ... , Partner, Canaan Partners; and Jordan Kramer , ...
(Date:7/29/2015)... CAMBRIDGE, Mass. , July 29, 2015 /PRNewswire/ ... leader in RNA-targeted therapeutics, and Akcea Therapeutics, its ... New England Journal of Medicine (NEJM) has published positive clinical ... volanesorsen (formerly ISIS-APOCIII Rx ) in patients with ... follows the December 2014 publication in the NEJM of ...
(Date:7/29/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... company serving the pharmaceutical, biotechnology and medical device industries, ... the United States , today announced ... of 2015 after the New York Stock Exchange closes ... morning, August 14, 2015 Shanghai time). The earnings release ...
Breaking Medicine Technology:MEDevice San Diego Offers Tips on Securing Financial Backing from Investors 2Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 2Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 3Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 4Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 5Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 6Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 7WuXi PharmaTech Schedules Second-Quarter 2015 Earnings Release 2
... ... Dysmenorrhea Pain Medication, HOBOKEN, N.J., June 18 A ... periods,affecting millions of women each year, can be reduced naturally ... maritime,pine tree. The multi- center field study, published in the ...
... the Need for Testosterone Screening in At-Risk ... ... from a 12-month,international, multi-center study showed that treatment for low,testosterone with ... and sexual function among,hypogonadal men with Type 2 diabetes and/or Metabolic ...
Cached Medicine Technology:New Study: Pine Bark Significantly Reduces Menstrual Pain 2New Study: Pine Bark Significantly Reduces Menstrual Pain 3Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome 2Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome 3
(Date:7/29/2015)... ... 29, 2015 , ... Avatar Solutions has received official approval from CMS to ... The CAHPS for PQRS Survey collects information about patients’ experiences of care ... must participate or they will receive a 2% penalty in 2017. At this point ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... Pharmacy Collaborative for retail healthcare providers begins in Kissimmee, Fla. The two-day ... and physician assistants can work together to expand access to affordable, high quality ...
(Date:7/29/2015)... ... 2015 , ... VideoLink , a leading provider of ... New York, NY, selected the ReadyCam on-site video studio to support their video ... access worldwide TV and cable news networks and participate in live TV interviews ...
(Date:7/29/2015)... ... July 29, 2015 , ... The ... the impact drinking and substance abuse is having on lost productivity, workplace accidents ... in the billions per year. [1] Will Wesch, Director of Admissions for ...
(Date:7/29/2015)... ... 29, 2015 , ... Today the nonprofit Alliance for ... Vaccination in Older Adults, that provides a comprehensive overview of the factors that ... health care experts can improve patient compliance. , Although influenza, pneumococcal, tetanus, and ...
Breaking Medicine News(10 mins):Health News:Avatar Solutions Approved to Administer CAHPS for Physician Quality Reporting System (PQRS) 2Health News:Avatar Solutions Approved to Administer CAHPS for Physician Quality Reporting System (PQRS) 3Health News:Last Chance for Pharmacists, Nurse Practitioners, Physician Assistants in Retail Clinics to Register for Collaborative Learning Program 2Health News:Last Chance for Pharmacists, Nurse Practitioners, Physician Assistants in Retail Clinics to Register for Collaborative Learning Program 3Health News:Last Chance for Pharmacists, Nurse Practitioners, Physician Assistants in Retail Clinics to Register for Collaborative Learning Program 4Health News:Columbia University Medical Center Installs a VideoLink ReadyCam® Video Studio on Campus; Medical Experts Able to Appear on Live TV at a Moment's Notice 2Health News:Columbia University Medical Center Installs a VideoLink ReadyCam® Video Studio on Campus; Medical Experts Able to Appear on Live TV at a Moment's Notice 3Health News:Workplace Trouble: Survey Reveals Sharp Escalation in Restaurant/Food Service Employee Drug Abuse 2Health News:Workplace Trouble: Survey Reveals Sharp Escalation in Restaurant/Food Service Employee Drug Abuse 3Health News:Vaccination Rates in Older Adults Fall Short of Targets 2Health News:Vaccination Rates in Older Adults Fall Short of Targets 3
... Executive Chairman & CEO Douglas MacLellan offers expert insight ... April 29 AMDL Inc. ... major operations in China, announced today its Executive Chairman ... featured in The Wall Street Transcript - ...
... pollution , , WEDNESDAY, April 29 (HealthDay News) -- More than ... exact, live and breathe in communities with dangerously high levels ... ten Americans live in areas dirty enough to send people ... and even dirty enough to kill," Charles D. Connor, president ...
... a preventative therapy for Type 1 diabetes, by making ... they would normally attack and destroy, prior to disease ... where the body attacks its own insulin producing cells. ... onset, usually in youth. People with Type 1 diabetes ...
... hold the key to stem cell treatments for motor neurone ... that these fish are able to produce motor neurones ... and breathing in humans when they repair damage to ... with a view to finding drugs that could kick-start the ...
... Audit Committee Members and Complies with Nasdaq Rule -INCLINE ... (Nasdaq: PDLI ) today announced that its ... vice president of finance and principal accounting officer."We are ... brings over twenty years of finance and accounting experience ...
... New analyses of data from the 16-Year Long-term ... Bayer HealthCare Pharmaceuticals, were presented at the American ... The study results showed that early and sustained ... sclerosis (MS) were more likely to avoid a ...
Cached Medicine News:Health News:Chinese Pharma Market Continues to Grow at a 5-7% Rate in 2009; AMDL Remains on Track to Meet FY09 Financial Targets 2Health News:Chinese Pharma Market Continues to Grow at a 5-7% Rate in 2009; AMDL Remains on Track to Meet FY09 Financial Targets 3Health News:More Than Half of Americans Living with Dirty Air 2Health News:More Than Half of Americans Living with Dirty Air 3Health News:Potential preventative therapy for Type 1 diabetes 2Health News:Zebrafish offer clues to treatments for motor neurone disease 2Health News:PDL BioPharma Appoints Karen J. Wilson as Vice President, Finance and Principal Accounting Officer 2Health News:New Analyses from 16-Year Follow-up Trial with Betaseron(R) Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes 2Health News:New Analyses from 16-Year Follow-up Trial with Betaseron(R) Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes 3Health News:New Analyses from 16-Year Follow-up Trial with Betaseron(R) Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes 4
Scoville Ruptured Disc Curettes, length 10" (254 mm), cup size 4 x 10 mm....
Karlin Lumbar Microdiscectomy Curette, length 9 1/2" (24.13 cm)....
Karlin XL Magnum Cup Curettes, extra long (XL) curettes, black handles, lightweight, length 13 1/4" (33.7 cm), handle length 8 1/2" (21 cm), handle diameter 1 1/4" (32 cm)....
Microsect Curette with increased cutting edge and modified shaft, 10"....
Medicine Products: